Uxin Clocks ~79% Revenue Growth In Q2

Uxin Ltd (NASDAQ:UXIN) reported second-quarter FY23 sales growth of 78.9% year-on-year, to RMB618.8 million ($87 million). The transaction volume for the…
  • Uxin Ltd (NASDAQ:UXIN) reported second-quarter FY23 sales growth of 78.9% year-on-year, to RMB618.8 million ($87 million).
  • The transaction volume for the quarter was 6,050 units, a 65.8% jump from last year.
  • The gross margin for the quarter was 1.3% versus 4.2% last year.
  • The operating loss for the quarter expanded to RMB(106.4) million or $(15) million.
  • The company held RMB24.4 million ($3.4 million) in cash and equivalents as of September 30, 2022.
  • Non-GAAP adjusted loss per share for the quarter was RMB(0.07) versus a loss of RMB (0.05) last year.
  • “As COVID-19 control measures ease in China and regulators continue to implement industry-boosting policies across the nation, we are confident and prepared to capitalize on the growing opportunities in the coming new year,” said Kun Dai, Founder, Chairman and CEO of Uxin.
  • Outlook: Uxin sees Q3 revenue of RMB450 million – RMB460 million.
  • Price Action: UXIN shares are trading higher by 7.28% at $3.39 in premarket on the last check Friday.
  • Photo Via Company
Total
0
Shares
Related Posts
Read More

Investor Optimism Improves Despite Nasdaq Settling Lower

The CNN Money Fear and Greed index showed an improvement in sentiment among investors followings signs that China’s government may begin to ease its strict COVID-19 restrictions amid protests in the country. The S&P 500 and Nasdaq Composite settled lower for a third session in a row on Tuesday after recording sharp losses in the previous session.

CRM

Read More

Celularity Announces Net Sales And Total Revenue Expectations; Expects Net Sales Of Its Biomaterial Products And Biobanking Businesses To Be In The Range Of $11.4M-$12.1M For Q4 2023 And $22.06M-$22.76M For FY23

Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year

CELU